Results 21 to 30 of about 122,145 (339)

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea [PDF]

Obesity Science & Practice
Background and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian, Yu‐Jie Huang, Cai‐Feng Yan, Shang‐Yong Feng, Dun‐Min She   +4 more
doaj   +2 more sources

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis [PDF]

ACR Open Rheumatology
Objective Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) are approved for weight loss, diabetes, and cardiovascular risk reduction. Despite widespread use, GLP‐1RAs have not been well studied in patients with rheumatoid arthritis (RA).
David A. Kellner, Elizabeth Dente, Vincent Tran, Travis Welsh, Victor Tran, Angshuman Saha, Joshua F. Baker, David A. Elashoff, Veena K. Ranganath   +8 more
doaj   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis

Frontiers in Endocrinology, 2021
ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Chin Meng Khoo, Chin Meng Khoo   +12 more
doaj   +1 more source

History of glucagon-like peptide-1 receptor agonists

Pharmacological Research
Radwan Darwish, Ghena Abu-Sharia, Alexandra E. Butler   +2 more
doaj   +2 more sources

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Circulation, 2017
M. Nauck, J. Meier, M. Cavender, Mirna Abd El Aziz, D. Drucker   +4 more
semanticscholar   +3 more sources

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner

Communications Biology, 2021
Li, Chen, Vong, Zhao et al. show that glucagon-like peptide-1 receptor agonist reverses transcriptomic aging signatures in mouse glial and neurovascular cells.
Zhongqi Li, Xinyi Chen, Joaquim S. L. Vong, Lei Zhao, Junzhe Huang, Leo Y. C. Yan, Bonaventure Ip, Yun Kwok Wing, Hei-Ming Lai, Vincent C. T. Mok, Ho Ko   +10 more
doaj   +1 more source

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

British medical journal, 2021
Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk. Design Network meta-analysis.
S. Palmer, B. Tendal, R. Mustafa, P. Vandvik, Sheyu Li, Q. Hao, David J. Tunnicliffe, M. Ruospo, P. Natale, V. Saglimbene, A. Nicolucci, David W. Johnson, M. Tonelli, M. Rossi, S. Badve, Yeoungjee Cho, Annie-Claire Nadeau-Fredette, M. Burke, L. Faruque, Anita M. Lloyd, Nasreen Ahmad, Yuanchen Liu, Sophanny Tiv, Tanya Millard, L. Gagliardi, N. Kolanu, Rahul D Barmanray, Rita McMorrow, Ana Karina Raygoza Cortez, Heath White, Xiang Chen, Xu Zhou, Jiali Liu, Andrea Flores Rodríguez, A. D. González-Colmenero, Yang Wang, Ling Li, S. Sutanto, Ricardo Cesar Solis, Fernando Diaz Gonzalez-Colmenero, R. Rodríguez‐Gutiérrez, M. Walsh, G. Guyatt, G. Strippoli   +43 more
semanticscholar   +1 more source

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers

Alzheimer's & Dementia, 2022
People with type 2 diabetes have increased risk of dementia. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they ...
C. H. Nørgaard, Sarah Friedrich, C. Hansen, T. Gerds, C. Ballard, D. Møller, L. Knudsen, K. Kvist, B. Zinman, E. Holm, C. Torp‐Pedersen, L. S. Mørch   +11 more
semanticscholar   +1 more source

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study

Obesity Surgery, 2023
Purpose Weight regain after bariatric surgery occurs in up to a third of patients and reduces treatment-associated health benefits. The efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RA) for treatment of type 2 diabetes mellitus and obesity ...
A. B. Jensen, F. Renström, S. Aczél, P. Folie, M. Biraima-Steinemann, Felix Beuschlein, S. Bilz   +6 more
semanticscholar   +1 more source

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu, Guillaume Mabilleau, Iepsen, Iepsen, Marie Pereira   +4 more
core   +5 more sources